Abstract: The invention is a battery clamshell plate comprising a plurality of laminate layers stacked and connected together. The laminate layers may be made of printed circuit board (PCB). The laminate layers may have cut outs to house battery cells, of which the battery cells are connected to the battery clamshell plate by friction or mechanical means. The invention considers strategies to minimize weight and to ensure resistance to shock and vibration failures. This invention also considers air cooling in between cells.

Abstract: A clamshell plate for a battery pack is configured to facilitate connection via adhesive to a plurality of battery cells. The clamshell plate includes: an exterior surface; a recess within the clamshell plate for accommodating a battery cell therein; a channel extending around at least a portion of an inner diameter of the recess in which adhesive can be accommodated to secure the clamshell plate to the battery cell; a manifold opening into the channel; and a vent hole from the channel to the exterior surface of the clamshell plate. A battery pack and a method can employ the clamshell plate.

Abstract: The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

Abstract: The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

Abstract: The invention concerns a scalable, large-scale castanospermine preparation method that yields levels of purity greater than 98% from castanospermine-containing plant sources, such as Castanospermum australe seed material.

Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

Abstract: A protective cap (1, 9, 12) for the partial covering of a pre-fitted or a fully fitted vehicle component (11). The protective cap (1, 9, 12) is made from a biogenic and/or renewable raw material.

Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

Abstract: The invention concerns a scalable, large-scale castanospermine preparation method that yields levels of purity greater than 98% from castanospermine-containing plant sources, such as Castanospermum australe seed material.

Abstract: The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

Abstract: A ball joint having a ball stud that has a joint ball fixed at one end; a housing that defines a longitudinal axis and has an interior area which receives the joint ball and a socket that is positioned between the housing and the joint ball. The housing has an open end that includes an opening through which the ball stud extends when the joint ball is received within the interior area of the housing. The open end of the housing is formed such that the opening has a diameter that is smaller than a diameter of the joint ball. A press-on ring engages with an outer surface of the housing at the open end so as to increase a pull-out performance of the ball joint.

Abstract: The system and method of making an asymmetrical buckling portion in a linkage member that is formed at the same time a hexagonal holding feature is being formed. The presence of the elongated groove drives the force of a buckling event asymmetrically through the inner tie rod ball stud near the area of failure, which influences the tie rod assembly to buckle in the direction of the groove, prior to other components in the linkage system and thus negates the effects of inner tie rod ball stud run-out tolerances that are present in conventional inner tie rod ball studs formed by machining.

Abstract: The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.

Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

Abstract: A ball joint having a ball stud that has a joint ball fixed at one end; a housing that defines a longitudinal axis and has an interior area which receives the joint ball and a socket that is positioned between the housing and the joint ball. The housing has an open end that includes an opening through which the ball stud extends when the joint ball is received within the interior area of the housing. The open end of the housing is formed such that the opening has a diameter that is smaller than a diameter of the joint ball. A press-on ring engages with an outer surface of the housing at the open end so as to increase a pull-out performance of the ball joint.

Abstract: The system and method of making an asymmetrical buckling portion in a linkage member that is formed at the same time a hexagonal holding feature is being formed. The presence of the elongated groove drives the force of a buckling event asymmetrically through the inner tie rod ball stud near the area of failure, which influences the tie rod assembly to buckle in the direction of the groove, prior to other components in the linkage system and thus negates the effects of inner tie rod ball stud run-out tolerances that are present in conventional inner tie rod ball studs formed by machining.

Abstract: The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.

Abstract: A system and method for detecting wear and/or failure of a ball joint. The system having a ball housing which retains a ball head of the ball joint therein. A ball race is received within the ball housing and receives the ball head of the ball joint. An inwardly facing surface of the ball race engages the ball head such that the ball head can pivot in relation to the ball housing. A detection component is supported by the ball race and is spaced from an exterior surface of the ball head by a set distance. The detection component issues an indicator signal to alert a driver when the detection component detects at least one of a worn or a failure condition of the ball joint.

Abstract: A method and system for determining a hardness of a component to be tested by utilizing an ultrasonic meter. The method and system both comprise selecting a component to be tested which has a longitudinal axis; positioning a probe of the ultrasonic meter for emitting a signal from an emitter of the probe into an end surface of the component to be tested and along the longitudinal axis of the component; emitting the signal from the emitter of the probe into the first surface of the component to be tested; passing the emitted signal through the component to be tested; reflecting the emitted signal via an opposed second surface of the component to be tested back toward a detector of the probe; detecting the reflected signal via the detector of the probe; and determining a hardness of the component to be tested based upon a velocity of the emitted signal.